Recent Finacing
Recent Raise
NovaDigm develops recombinant-protein vaccines targeting Candida and Staphylococcus aureus (including MRSA); lead NDV-3 (Als3) showed cross-kingdom preclinical efficacy and advanced from Phase 1 safety/immunogenicity to Phase 2 RVVC trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors